The In-Vivo study of microencapsulated Glimepiride In Long Evans Rats

Diabetes is a severe disease that occurs when the pancreatic does not produce enough blood insulin, or on the other hand, when the system cannot effectively use the blood insulin it produces. It is essential to tried out alternate and less costly medications, which can bring down blood sugar levels. From this point of view the Glimepiride has been used experimentally to identify hypoglycemic effect. The sustained release Glimepiride formulation is useful to manage the blood sugar level for the prolonged period of time. It is suitable to design the dosage form due to its short biological half-life of 5 hours and advantageous for diabetic patients. The objective of this study was to investigate the hypoglycemic effect of microencapsulated Glimepiride in biological condition.